Header cover image

French (CAC) Biotech Industry Analysis

UpdatedJan 20, 2022
DataAggregated Company Financials
Companies38
  • 7D-10.0%
  • 3M-22.9%
  • 1Y-36.2%
  • YTD-20.3%

Over the last 7 days, the Biotech industry has dropped 10%, driven by a decline by Valneva of 19%. Meanwhile, Acticor Biotech SAS actually outperformed within the industry, gaining 41% in the last week. However, the industry is down 36% over the past year.

Industry Valuation and Performance

Has the French Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Fri, 21 Jan 2022€5.6b€932.4m-€677,940,801.003.2x
Sun, 19 Dec 2021€7.3b€925.9m-€681,351,448.003.1x
Tue, 16 Nov 2021€6.9b€926.2m-€682,868,763.002.4x
Thu, 14 Oct 2021€6.1b€891.9m-€679,082,032.002.9x
Sat, 11 Sep 2021€7.8b€878.8m-€620,422,159.122.7x
Mon, 09 Aug 2021€6.5b€899.6m-€600,532,159.122.7x
Sun, 02 May 2021€7.2b€882.0m-€570,006,611.923.1x
Wed, 03 Feb 2021€7.1b€911.8m-€514,619,691.4222.3x
Sat, 07 Nov 2020€4.7b€737.3m-€578,081,678.948.7x
Fri, 31 Jul 2020€4.1b€624.3m-€569,407,653.4429.7x
Mon, 04 May 2020€5.0b€608.4m-€585,561,414.9618.8x
Thu, 06 Feb 2020€4.4b€548.6m-€625,688,103.6716.8x
Sun, 10 Nov 2019€3.4b€544.8m-€607,268,613.1056.4x
Sat, 03 Aug 2019€4.3b€547.0m-€661,534,274.6038.9x
Tue, 07 May 2019€5.0b€561.3m-€612,527,196.0024x
Fri, 08 Feb 2019€4.1b€558.2m-€577,409,059.2022.9x
PE Ratio

22.9x

Total Market Cap: €4.1bTotal Earnings: -€577,409,059.20Total Revenue: €558.2m0%0%0%3 Year10 Year
202020212022

Current Industry PE: There are only 3 profitable companies in this industry, so there is insufficient data to make an industry-wide assessment of PE.

Past Earnings Growth: The earnings for companies in the Biotechs industry have deteriorated over the last three years, while revenues for these companies have grown 19% per year. This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the French Biotech industry?

Biotech-10.01%

Industry PE: Investors are most optimistic about the Biotech industry even though it's trading below its 3-year average PE ratio of 19.3x. However analysts are expecting annual earnings growth of 53%, which is lower than the prior year's growth of 158% per year. So the market might believe that analysts are underestimating future growth.

Forecasted Growth: Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 53% over the next 5 years. However this is lower than its past earnings growth rate of 158% per year.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TNG Transgene€2.655.0%
+€12.2m
0.4%PS28.8x
ALACT Acticor Biotech SAS€6.5421.3%
+€12.1m
n/aPB16.8x
IVA Inventiva€11.201.8%
+€8.2m
-28.0%PS81.1x
ALINT IntegraGen€1.4019.5%
+€1.5m
-33.4%PS1x
ALGEN genOway Société anonyme€4.592.7%
+€1.1m
36.9%PS2.3x
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

ALSEN

€0.87

Sensorion

7D

-51.9%

1Y

-51.5%

ALCLS

€6.27

Cellectis

7D

-5.4%

1Y

-76.4%

IVA

€11.20

Inventiva

7D

1.8%

1Y

-28.0%

LYS

€1.87

Lysogene

7D

1.1%

1Y

-26.4%